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Abstract
Background: Occult hepatitis B virus (HBV) infection (OBI) is characterized by HBV DNA persistence even though
the pattern of serological markers indicates an otherwise resolved HBV infection. Although OBI is usually clinically
silent, immunocompromised patients may experience reactivation of the liver disease.
Case presentation: We report the case of an individual with human immunodeficiency virus (HIV) infection and
anti-HBV core antibody positivity, who experienced severe HBV reactivation after discontinuation of lamivudine-
including antiretroviral therapy (ART). HBV sequencing analysis showed a hepatitis B surface antigen escape mutant
whose presence in an earlier sample excluded reinfection. Molecular sequencing showed some differences
between two isolates collected at a 9-year interval, indicating HBV evolution. Resumption of ART containing an
emtricitabine/tenofovir combination allowed control of plasma HBV DNA, which fell to undetectable levels.
Conclusion: This case stresses the ability of HBV to evolve continuously, even during occult infection, and the
effectiveness of ART in controlling OBI reactivation in HIV-infected individuals.
Background
Occult hepatitis B virus (HBV) infection (OBI) is, by
definition, characterized by infectious HBV DNA in
liver, blood, or both, in the absence of hepatitis B sur-
face antigens (HBsAg) [1]. Isolated anti-HBV core anti-
bodies (anti-HBc) have been shown to be a predictive
marker of OBI [2]. Isolated anti-HBc [3,4] and OBI are
often seen in patients with human immunodeficiency
virus (HIV) infection [5,6], where they are more preva-
lent than in non-coinfected individuals [7]. Reactivation
of chronic HBV in presence of HBsAg has been
reported in immunosuppressed subjects and in those
with HIV infection following discontinuation of antire-
troviral therapy (ART) [8,9].
There are few reports addressing OBI reactivation
during HIV infection [10,11] and fewer still providing
an extensive description of the molecular characteristics
of occult HBV reactivation [12]. Nucleot(s)ide analogues
(NA) lamivudine, emticitabine and tenofovir are known
to be effective against both HIV and HBV, providing a
unique opportunity to treat coinfected patients [13,14],
but little information is available to establish whether
resumption of ART for HIV/HBV coinfection may
restore control of HBV replication after OBI
reactivation.
Case presentation
A 46-year-old woman with a 25-year history of HIV dis-
ease, who experienced two episodes of occult HBV reac-
tivation after interrupting a lamivudine-containing ART
regimen. At the time of the diagnosis of HIV infection
(October 1985) she also tested negative for HBsAg and
positive for anti-HBsAg and anti-HBc (table 1). Lamivu-
dine-containing ART was started in November 1996 and
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reasons (table 2). In addition, the patient did not fully
adhere to therapy, and complete suppression of HIV vir-
emia was never obtained (not shown). In September
2000 she discontinued the ART treatment; in few
months HIV RNA levels rose to more than 470,000
copies/ml and CD4+ T cell counts dropped to 9/mmc
(table 2), leading to two episodes of esophageal candi-
diasis, interstitialp n e u m o n i ad u et oChlamydia pneu-
moniae, and disseminated Mycobacterium avium
infection (not shown). ART including lamivudine and
tenofovir, was resumed in April 2002 and continued
until September 2009. Improved adherence to treatment
resulted in undetectable plasma HIV-RNA and high-
level immune reconstitution (tables 1 and 2).
Of note, since 1985 AST and ALT values were consis-
tently in the normal range except on two occasions
(May 1999, not shown, and January 2001, table 1), when
slight increases were noted but not further investigated.
Another interruption of ART in October 2009 resulted
in a sharp rise in aminotransferase levels to over 2,500
U/l in February 2010 (table 1), while CD4+ T cell
counts fell from 531 to 291/mmc and HIV-RNA rose to
>80,000 copies/ml. Antibodies against hepatitis C and
hepatitis D virus were negative, but detection of
serological markers of overt HBV infection (table 1) led
to a diagnosis of OBI reactivation, which was further
investigated at the molecular level.
A portion of the polymerase gene was sequenced
using the PCR product obtained with primers P1 (for-
ward outer = 5’-TCTAGACTCGTGGTGGACTTCTC)
and P4 (reverse outer = 5’-TACAGAGAAAGGCCTTG-
TAAGTTG) which amplified an 880 bp fragment of
HBV DNA from nucleotide 249 to 1128 (numbered
according to an EcoRI site). This allowed analysis of
mutations in the overlapping surface (s) and reverse
transcriptase (rt) genes of HBV. As shown in table 3
and Figure 1, the patient harboured a genotype D (sub-
type D1) HBV strain and no NA resistance-associated
mutations were selected in the polymerase gene. Inter-
estingly, envelope escape variants were detected due to
G145R, D144DE and P142LP mutations. The presence
of HBsAg escape variants and the availability of seven
frozen samples collected between October 2000 and
May 2009 prompted a retrospective analysis for the
molecular and serological markers of viral activity.
Three of the seven samples collected during the amino-
transferase “blips” between October 2000 and May 2001
exhibited very low-level viremia (table 1) using highly
sensitive HBV RealTime (Abbott Laboratories. Abbott
Table 1 Sequential serological, biochemical and virological findings in an HIV-infected individual with markers of prior
HBV infection at baseline.
Characteristics Date (month/year)
10/
85
11/
87
10/00
1 01/01
1 05/01
1 11/
06
1
01/
07
1
01/
08
1
05/
09
12/09 02/10 02/
10
03/
10
04/
10
05/
10
07/
10
HBsAg (IU/ml) NEG NEG 0.00 0.00 0.00 0.00 0.00 0.00 0.00 – 168 183 132 66 0.1 0.0
Anti-HBs (mIU/ml) POS POS <10 <10 <10 <10 <10 <10 <10 – 140 124 87 61 50 24
Anti-HBc POS POS POS POS POS POS POS POS POS – POS POS POS – POS POS
Anti-HBc IgM NEG NEG – – – –––– –POS POS POS NEG ––
HBeAg NEG NEG – – – –––– –POS NEG NEG –––
Anti-HBe NEG NEG – – – –––– –POS POS POS –––
HBV DNA (IU/ml) ––R (3) R (7) 19 NR NR NR NR – 88,185 5,622 998 26 R (4) NR
AST (U/l) 17 19 31 58 30 20 21 23 28 80 2,702 143 41 – 23 19
ALT (U/l) 14 16 35 68 37 14 14 14 19 111 2,577 306 42 – 17 21
CD4+ T (cells/µl) 891 883 48 29 48 478 580 516 513 304 291 –––423 333
HIV-RNA
2(copies/
ml)
––147,018 222,107 146,707 <50 <50 NR NR 80,558 –– 734 – NR NR
Antiretroviral
therapy
Naive Naive No
3 No
3 No
3 Yes
4 Yes
4 Yes
4 Yes
4 No
5 No
5 Yes
6 Yes
6 Yes
6 Yes
6 Yes
6
IU/ml = International Units/milliliter; mIU/ml = International milliunits/ml; U/l = Units/liter; NEG = negative; POS = positive; R = reactive below cut-off (<10IU/ml);
HBV DNA calculated by the regression curve in brackets; NR = not reactive; – = not determined.
1molecular and serological markers of HBV infection were retrospectively determined in February 2010 using automated Abbott HBV RealTime and Abbott
ARCHITECT HBV assays, respectively
2HIV viremia was evaluated by Versant HIV RNA assay 3.0 (bDNA; Siemens Healthcare Diagnostics, Deerfield, IL) up to 01/2007 and by Abbott HIV RealTime since
01/2008.
3Previous antiretroviral therapy (Didanosine, Lamivudine, Nevirapine) was started on 04/2000 and interrupted on 08/2000; Lamivudine daily dose was 300 mg.
4Therapy was resumed in 02/2002 with different drug combinations including Lamivudine (300 mg daily) with or without Tenofovir (245 mg daily).
5Therapy (Lamivudine and Atazanavir) was interrupted on 10/2009.
6Therapy was resumed in 02/2010, including co-formulated Emtricitabine/Tenofovir (200/245 mg daily) plus boosted Darunavir.
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per millilitre [IU/mL]), and serological analysis revealed
isolated anti-HBc. Attempts to obtain an overlapping
polymerase and surface antigen sequence was successful
with the May 2001 specimen, using a 5× concentration
and nested PCR with inner primers P2 (forward inner =
5’-TCCTGTCCTCCAACTTGTCCTG) and P3 (reverse
inner = 5’-TGTGGCAATGTACCCCAACTTCCA) that
amplified a 571 bp fragment internal to the P1-P4 pro-
duct, from nucleotide 346 to 916. This sequence showed
the G145R and P142L, but not the D144DE HBsAg
escape variant. The sample also contained the V224AV
quasispecies, which was subsequently undetectable
(table 3 and Figure 1). Although we cannot exclude that
the different quasispecies were present in 2010, our date
indicate that during the course of treatment, the species
Table 2 Changes in ART during follow-up and reasons for each change.
ART combination Start Stop Reasons for the changes Lowest number of CD4+ T
cells/mmc
Highest HIV-RNA load
(copies/ml)
Zidovudine, Lamivudine 11/1996 07/1997 Upgrade 147 –
Zidovudine, Lamivudine,
Saquinavir
08/1997 02/2000 Poor adherence, virological
failure
50 90,387
Stavudine, Lamivudine,
Efavirenz
03/2000 04/2000 Skin rash 95 1,164
Stavudine, Lamivudine,
Nevirapine
05/2000 08/2000 Patient decision 65 1,245
INTERRUPTION 09/2000 01/2002 – 9 472,578
Stavudine, Lamivudine 02/2002 04/2002 Upgrade ––
Stavudine, Lamivudine,
Lopinavir/r*
05/2002 04/2003 Patient decision, diarrhea 74 <50
Tenofovir, Lamivudine,
Indinavir/r*
05/2003 01/2009 Patient decision 245 <50
Didanosine, Lamivudine,
Atazanavir
02/2009 04/2009 Simplification 516 <40
Lamivudine, Atazanavir 05/2009 09/2009 Patient decision 531 119
INTERRUPTION 10/2009 02/2010 – 291 80,558
Emtricitabine/Tenofovir,
Darunavir/r*
02/2010 –– 333 734
*r = boosted ritonavir.
Table 3 Genetic variability of hepatitis B virus during occult infection.
Sequence information
Sample ID (HBV viral load) SL05/2001 (19 IU/ml)
Genotype (subtype) D (D1 - 97.95%
1)
rt-HBV mutations: aa 79-255
3 N118H, Y135S, R153Q, N248H
2
s-HBV mutations: aa 71-227stop
3 R122K, P142LP, G145R, F179FS, V224AV
2
Escape mutations 142L, 145R
Resistance prediction None
4
Sample ID (HBV viral load) SL02/2010 (88,185 IU/ml)
Genotype (subtype) D (D1 - 98.23%
1)
rt-HBV mutations: aa 43-330
3 N118H, Y135S, R153KQ, N248H
2
s-HBV mutations: aa 35-227stop
3 R122K, P142LP, D144DE, G145R, F179FS
2
Escape mutations 142L, 144E, 145R
Resistance prediction None
4
1 percent identity to the subtype as reported by HIV-GRADE_HBV-tool analysis (software available at http://www.hiv-grade.de/hbv_grade/deployed/grade.pl?
program=hbvalg).
2 mutated residues are defined with respect to the HBV genotype D consensus sequence, residues in bold indicate changes involving both rt and s genes.
3 aa = amino acid; the range of sequenced amino acid residues covers the whole region of rt-HBV involved by antiviral resistance and the “a” determinant
neutralizing antibody-binding domains of the s-HBV gene; aa numbered according to Stuyver et al [26].
4 the resistance prediction and reference sequence were assessed by HIV-GRADE_HBV-tool coupled with the interpretative algorithm Geno2Pheno [hbv]
(available at http://hbv.bioinf.mpi-inf.mpg.de/index.php).
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species with V224A decreased in proportion. Altogether
these data can be regarded as signs of HBV evolution:
however, we acknowledge that lacking of cloning analy-
sis of HBV quasispecies is a possible limitation to these
conclusions.
The patient resumed ART to control HIV replication
and counteract HBV reactivation. A regimen including
emtricitabine/tenofovir plus boosted darunavir was pre-
scribed in mid February 2010. After three months ami-
notransferase levels reverted to normal; follow-up of
serological HBV markers showed the sequential disap-
pearance of hepatitis B e antigen (HBeAg), IgM class
anti-HBc, and HBsAg. Plasma HBV DNA gradually fell
to undetectable levels (table 1).
Conclusions
We describe the case of an HIV-infected patient with
serological evidence of resolved HBV infection who
experienced two distinct episodes of OBI reactivation
after interrupting of lamivudine-containing ART regi-
mens. In both cases, reintroduction of ART including
HBV-active NA (lamivudine or emtricitabine/tenofovir)
was followed by aminotransferase normalization and
clearance of plasma HBV DNA. Different results have
been reported in two HIV/HBV coinfected patients
A
RT gene sequences
                        10         20         30         40         50         60         70         80
consensus D     EDWGPCAEHG EHHIRIPRTP ARVTGGVFLV DKNPHNTAES RLVVDFSQFS RGNYRVSWPK FAVPNLQSLT NLLSSNLSWL
SL05_2001       .......... .......... .......... .......... .......... .......... .......... ........--
SL02_2010       .......... .......... .......... .......... ..-------- ---------- ---------- ----------
                        90        100        110        120        130        140        150        160
consensus D     SLDVSAAFYH LPLHPAAMPH LLVGSSGLSR YVARLSSNSR IFNHQHGTMQ NLHDYCSRNL YVSLLLLYQT FGRKLHLYSH
SL05_2001       ---------- ---------- ---------- -------H-- ---------- ----S----- ---------- --Q-------
SL02_2010       ---------- ---------- ---------- -------H-- ---------- ----S----- ---------- --Q-------
                                                                                               K
 170        180        190        200        210        220        230        240
consensus D     PIILGFRKIP MGVGLSPFLL AQFTSAICSV VRRAFPHCLA FSYMDDVVLG AKSVQHLESL FTAVTNFLLS LGIHLNPNKT
SL05_2001       ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
SL02_2010       ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
                       250        260        270        280        290        300        310        320
consensus D     KRWGYSLNFM GYVIGCYGSL PQDHIIQKIK ECFRKLPVNR PIDWKVCQRI VGLLGFAAPF TQCGYPALMP LYACIQSKQA
SL05_2001       -------H-- -----..... .......... .......... .......... .......... .......... ..........
SL02_2010       -------H-- ---------- ---------- ---------- ---------- ---------- ---------- ----------
                       330        340
consensus D     FTFSPTYKAF LCKQYLNLYP VARQ
SL05_2001       .......... .......... ....
SL02_2010       --------.. .......... ....
B
HBsAg gene sequences
                    10         20         30         40         50         60         70         80
consensus D     MENITSGFLG PLLVLQAGFF LLTRILTIPQ SLDSWWTSLN FLGGTTVCLG QNSQSPTSNH SPTSCPPTCP GYRWMCLRRF
SL05_2001       .......... .......... .......... .......... .......... .......... .......... ----------
SL02_2010       .......... .......... .......... ....------ ---------- ---------- ---------- ----------
                        90        100        110        120        130        140        150        160
consensus D     IIFLFILLLC LIFLLVLLDY QGMLPVCPLI PGSSTTSTGP CRTCTTPAQG TSMYPSCCCT KPSDGNCTCI PIPSSWAFGK
SL05_2001       ---------- ---------- ---------- ---------- -K-------- ---------- -L--R----- ----------
                                                                                   P
SL02_2010       ---------- ---------- ---------- ---------- -K-------- ---------- -L-ER----- ----------
                                                                                   P D
 170        180        190        200        210        220
consensus D     FLWEWASARF SWLSLLVPFV QWFVGLSPTV WLSVIWMMWY WGPSLYSILS PFLPLLPIFF CLWVYI*
SL05_2001       ---------- --------S- ---------- ---------- ---------- ---------- ---A---
                                   F                                                 V
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F
Figure 1 Alignment of HBV genes. Alignment of the amino acid (aa) sequences of the HBV polymerase (A) and surface (B) genes amplified
from samples collected during two episodes of OBI reactivation. The genotype D consensus sequence is shown as a reference in the alignment
performed by HIV-GRADE_HBV-tool. Dashes indicate identity to the reference, points indicate sequence gaps due to primer design. Substitutions
and ambiguities indicating presence of quasispecies in the direct sequence are shown. Differences between the two sequences are in bold. * =
stop codon; aa numbered according to Stuyver et al [26]. The two sequences have been submitted to the GenBank and assigned accession no.
JF827279 (SL05_2001), JF827280 (SL02_2010).
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unclear, since only few cases of OBI reactivation among
HIV-infected individuals have been reported to date.
Emergence of HBV drug resistance following OBI reacti-
vation was observed neither in our patient nor in the
one described by Bagaglio and co-workers [12]; residual
HBV replication before the overt phase of occult HBV
reactivation was excluded in both patients. However,
residual HBV replication and reactivation without prior
HBV DNA positivity have both been described in HIV-
infected patients [15,16].
Interestingly, OBI reactivation in our patient was trea-
ted with a drug combination including emtricitabine
and tenofovir, while Bagaglio and co-workers used a sin-
gle-drug tenofovir-based approach, and Chamorro and
colleagues a scale up approach where tenofovir was
introduced years after lamivudine [10]. Conceivably, dif-
ferent HBV-active regimens may determine different
outcomes in OBI reactivation, and combination therapy
may have in principle better chances to obtain long-
term control of HBV replicati o nt h a ns i n g l e - d r u gr e g i -
mens, especially in the context of HIV-related immune
suppression.
One of the most intriguing aspect of HBV pathogen-
esis is the accumulation, already in the early phase of
infection, of covalently closed circular (ccc)DNA in the
nuclei of infected hepatocytes, which is the basis for the
establishment of viral persistence. cccDNA is the hepatic
reservoir for HBV infection, found in all patients studied
up to a decade after resolution [17] and in 50% of
patients who had acute self-limited HBV infection 30
years previously [18]. Intrahepatic cccDNA can be con-
sidered as a candidate for OBI reactivation when immu-
nological host conditions deteriorate.
In our patient molecular analysis of HBV DNA during
reactivation disclosed an HBsAg escape variant, as
shown by G145R and D144DE mutations in the HBsAg
“a” determinant. Since HBV reinfection could not be
completely ruled out, we analyzed the serum and plasma
samples collected during the previous aminotransferase
“blip”, and found that the G145R variant was already
present at that time.
Due to overlapping envelope and polymerase genes,
the s-G145R variant is associated with the rt-R153Q
mutation, which results in expression of an altered poly-
merase that is replication competent but seems to have
reduced replication efficiency [19-21]. Among the few
differences observed between the direct sequences of the
2001 and 2010 specimens, the s-HBV D144E variant
seems to be important, since it determines a Q153K
back mutation at the rt-HBV level. It is conceivable that
rt-153K could be a secondary mutation connected with
a fitness gain. Interestingly, coexistence of HBsAg and
anti-HBs in 2010 specimens could be explained by
presence of heterologous subtype-specific antibodies
possibly directed against an HBsAg subtype different
from HBsAg expressed in the past (primary) infection.
At least five remarkable mutations were detected within
the neutralizing epitope cluster of the surface protein in
the genotype D consensus sequence, of which the
D144E mutation has been described as a variant with
“d” determinant opposite to the “y” determinant more
frequently detected in genotype D [22]. Although it is
impossible to establish whether this variant emerged in
the 9-year interval between the two OBI episodes, or
during the latest reactivation, our data indicate that
HBV evolution may have occurred during OBI, and that
this and some other mutations may have led to the
induction of less effective antibody response against a
reactivated virus.
OBI reactivation is a consequence of deteriorated
immune function [23,24]; in our patient the overt
phase of severe HBV reactivation arose in conjunction
with decreased CD4+ T cell counts. However, clinical
and biochemical levels reflecting severe HBV reactiva-
tion were not observed at other times when the
patient’s immune status was profoundly impaired (see
table 2): this was not a surprise, in that a severe reacti-
vation of hepatitis B requires a competent immune
systems, and this is what happened during immune
reconstitution in the absence of anti-HBV active drugs.
Overall, it may be speculated that a qualitative, rather
than a quantitative worsening of HBV-specific T cell
responses may favour OBI reactivation in HIV-infected
patients. Notably, persistence of functional T cell
response has been reported in individuals with OBI
and in HBsAg-inactive carriers [25].
The clinical significance of occult hepatitis is still a
matter of controversy and further studies should exam-
ine the long-term clinical implications of occult HBV in
HIV-infected patients.
In summary, this case stresses that ART for HIV/
HBV coinfection can control OBI reactivation in HIV-
infected individuals, and that in patients with previous
HBV infection the withdrawal of anti-HIV drugs with
activity against HBV must be approached with caution.
Moreover, molecular HBV sequencing data support the
hypothesis that HBV cccDNA, is not only the genetic
archive for resistant viral genome emerging during
treatment of chronic HBV, but also the genetic reser-
voir allowing continuous HBV evolution, through
ongoing low-level replication, even during occult
infection.
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